AI Article Synopsis

  • This study investigated how low-density lipoprotein cholesterol (LDL-C) levels impact recovery after intravenous thrombolysis (IVT) in stroke patients, based on whether they used statins before the stroke.
  • Among the 4711 patients analyzed, those with low to intermediate LDL-C levels did not show improved outcomes compared to those with high LDL-C, indicating that overall LDL-C levels alone are not linked to recovery at 3 months post-treatment.
  • However, for patients who took statins before their stroke, lower LDL-C levels were associated with better recovery outcomes, suggesting that statin use may influence how LDL-C affects recovery after an ischemic stroke.

Article Abstract

This study aimed to elucidate whether low-density lipoprotein cholesterol (LDL-C) levels differentially affect functional outcomes after intravenous thrombolysis (IVT) depending on prestroke statin use. Patients with acute ischemic stroke treated with IVT were categorized into low, intermediate, and high LDL-C groups based on LDL-C levels at admission (< 100/100-130/ > 130 mg/dl, respectively). Multivariable logistic regression analyses were performed to explore the relationships between LDL-C and clinical outcomes (good outcomes at 3 months, modified Rankin Scale scores 0-2). The interaction between LDL-C levels and prestroke statin use regarding functional outcomes was investigated. Among the 4711 patients (age, 67 ± 12 years; males, 62.1%) who met the eligibility criteria, compared with the high LDL-C group, the low and intermediate LDL-C groups were not associated with good outcomes at 3 months according to the multivariable analysis. A potential interaction between the LDL-C group and prestroke statin use on good outcomes at 3 months was observed (P = 0.07). Among patients with prestroke statin use, low (aOR 1.84 [1.04-3.26]) and intermediate (aOR 2.31 [1.20-4.47]) LDL-C groups were independently associated with a greater likelihood of having a 3-month good outcome. Our study showed that LDL-C was not associated with a 3-month good outcome, but prestroke statin use could modify the influence of LDL-C levels on functional outcomes after IVT.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9474509PMC
http://dx.doi.org/10.1038/s41598-022-19852-8DOI Listing

Publication Analysis

Top Keywords

prestroke statin
24
functional outcomes
16
ldl-c levels
16
good outcomes
12
outcomes 3 months
12
ldl-c
11
outcomes
8
outcomes intravenous
8
intravenous thrombolysis
8
low intermediate
8

Similar Publications

Background: Elevated low-density lipoprotein cholesterol is a risk factor for atherosclerotic cardiovascular disease, including acute ischemic stroke (AIS), due to large- and small-vessel disease. Cholesterol management guidelines recommend lipid-lowering therapy (LLT) to prevent atherosclerotic cardiovascular disease events. This study assessed use of LLT at the time of AIS according to guideline recommendations and determined the association of prestroke LLT use with stroke severity.

View Article and Find Full Text PDF
Article Synopsis
  • * Researchers analyzed data from over 42,000 patients, identifying key variables like age, sex, and health conditions that affect long-term survival.
  • * A predictive tool named SMART-M was developed, showing strong performance with C-statistics of approximately 0.806 for the training group and 0.803 for the validation group, indicating its reliability in mortality prediction.
View Article and Find Full Text PDF
Article Synopsis
  • A study evaluated the clinical and economic impact of stroke in French patients with type 2 diabetes (T2D), finding that 4.6% of participants experienced a stroke requiring hospitalization between 2012 and 2018.
  • The research indicated that ischemic strokes were significantly more common than hemorrhagic strokes, with higher associated rates of cardiovascular disease, stroke recurrence, and mortality in hemorrhagic cases during the follow-up period.
  • Treatment patterns revealed a slight increase in the prescription of certain glucose-lowering medications over time, highlighting ongoing health management challenges for T2D patients after experiencing a stroke.
View Article and Find Full Text PDF

Objectives: To investigate whether post-stroke statin therapy reduces subsequent major vascular events in statin-naïve patients with pretreatment low-density lipoprotein cholesterol (LDL-C) below the recommended target (≤70 mg/dL for atherosclerotic stroke and ≤100 mg/dL for non-atherosclerotic stroke) at stroke onset.

Methods: Patients from an ongoing stroke registry who had an ischemic stroke between 2011 and 2020 were screened. Statin naïve patients with baseline LDL-C below the target were assessed.

View Article and Find Full Text PDF

Effectiveness of statins on outcomes of patients with Embolic Stroke of Undetermined Source (ESUS).

J Stroke Cerebrovasc Dis

January 2024

Department of Neurology, Faculty of Medical Sciences of Santa Casa de São Paulo, Dr. Cesário Motta Júnior Street 112, 01221-020, São Paulo, Brazil.

Background: Statins are highly recommended as a secondary prevention strategy after a stroke. Embolic Stroke of Undetermined Source (ESUS) accounts for up to one fifth of cases of ischemic stroke. There is a lack of studies investigating the effectiveness of statins in this subgroup of patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!